Sign In
Last checked at 
3 Nov 2025 11:32
3 November 2025
Kromek Group plc
("Kromek", the "Company" or the "Group")
Director Share Purchase
Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that, on 31 October 2025, Matthew Boyle, Non-executive Director of the Company, purchased 285,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 6.74p per Ordinary Share.
Following this transaction, Mr. Boyle holds 285,000 Ordinary Shares, representing 0.04% of the Company's issued share capital.
Enquiries
Kromek Group plc | |
Arnab Basu, CEO Claire Burgess, CFO | +44 (0)1740 626 060 |
| |
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern - ECM Michael Johnson - Sales | +44 (0)20 7220 0500
|
Gracechurch Group (Financial PR) | |
Harry Chathli/Claire Norbury | +44 (0)20 4582 3500 |
Kromek Group plc
Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.
The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.
In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.
Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| Matthew Boyle | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Non-executive Director | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Kromek Group plc | |||
b)
| LEI
| 213800VLHYXGHEX5VQ48
| |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 1 penny each | |||
Identification code | GB00BD7V5D43 | ||||
b)
| Nature of the transaction
| Purchase of ordinary shares | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
6.74p | 285,000 | ||||
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A | |||
e)
| Date of the transaction
| 31 October 2025 | |||
f)
| Place of the transaction
| London Stock Exchange | |||
Follow the stocks
